Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
An immunosuppressed microenvironment distinguishes lateral ventricle–contacting glioblastomas
Todd Bartkowiak, … , Rebecca A. Ihrie, Jonathan M. Irish
Todd Bartkowiak, … , Rebecca A. Ihrie, Jonathan M. Irish
Published May 16, 2023
Citation Information: JCI Insight. 2023;8(12):e160652. https://doi.org/10.1172/jci.insight.160652.
View: Text | PDF
Research Article Immunology Oncology

An immunosuppressed microenvironment distinguishes lateral ventricle–contacting glioblastomas

  • Text
  • PDF
Abstract

Radiographic contact of glioblastoma (GBM) tumors with the lateral ventricle and adjacent stem cell niche correlates with poor patient prognosis, but the cellular basis of this difference is unclear. Here, we reveal and functionally characterize distinct immune microenvironments that predominate in subtypes of GBM distinguished by proximity to the lateral ventricle. Mass cytometry analysis of isocitrate dehydrogenase wild-type human tumors identified elevated T cell checkpoint receptor expression and greater abundance of a specific CD32+CD44+HLA-DRhi macrophage population in ventricle-contacting GBM. Multiple computational analysis approaches, phospho-specific cytometry, and focal resection of GBMs validated and extended these findings. Phospho-flow quantified cytokine-induced immune cell signaling in ventricle-contacting GBM, revealing differential signaling between GBM subtypes. Subregion analysis within a given tumor supported initial findings and revealed intratumor compartmentalization of T cell memory and exhaustion phenotypes within GBM subtypes. Collectively, these results characterize immunotherapeutically targetable features of macrophages and suppressed lymphocytes in GBMs defined by MRI-detectable lateral ventricle contact.

Authors

Todd Bartkowiak, Sierra M. Lima, Madeline J. Hayes, Akshitkumar M. Mistry, Asa A. Brockman, Justine Sinnaeve, Nalin Leelatian, Caroline E. Roe, Bret C. Mobley, Silky Chotai, Kyle D. Weaver, Reid C. Thompson, Lola B. Chambless, Rebecca A. Ihrie, Jonathan M. Irish

×

Figure 5

Enrichment of CD32+CD44+ macrophages proximal to the LV.

Options: View larger image (or click on image) Download as PowerPoint
Enrichment of CD32+CD44+ macrophages proximal to the LV.
(A) Representat...
(A) Representative t-SNE plots indicating the CD45+ leukocyte fraction infiltrating focal subregions biopsied from the bulk tumor mass of patients with NC-GBM (n = 2) or C-GBM (n = 5). Paired biopsies were collected from 1) superficial (black/gray), 2) medial (light blue/light red), or 3) deepest region available to safe surgical resection (dark blue/dark red). (B) The frequency of each indicated immune subset was calculated as a fraction of the total cell fraction in the biopsy (leukocytes) or as a fraction of the total leukocyte pool in each sample. S, superficial tumor tissue; M, medial tumor tissue; D/V, deep/ventricular tumor tissue. (C) Frequency of memory CD8+ T cell populations within subregions from NC-GBM (blue) or C-GBM (red). Tn, naive T; Temra, effector memory CD45RA+; Tem, effector memory; Tcm, central memory. (D) Frequency of exhausted CD8+ T cell populations within tumor subregions. Each line in B–D represents 1 paired patient sample. One-way ANOVA with Tukey’s multiple comparisons test calculated statistical significance. * = P < 0.05.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts